These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 28361333)

  • 21. Methotrexate polyglutamates as a potential marker of adherence to long-term therapy in children with juvenile idiopathic arthritis and juvenile dermatomyositis: an observational, cross-sectional study.
    Hawwa AF; AlBawab A; Rooney M; Wedderburn LR; Beresford MW; McElnay JC
    Arthritis Res Ther; 2015 Oct; 17():295. PubMed ID: 26493320
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Generation of novel pharmacogenomic candidates in response to methotrexate in juvenile idiopathic arthritis: correlation between gene expression and genotype.
    Moncrieffe H; Hinks A; Ursu S; Kassoumeri L; Etheridge A; Hubank M; Martin P; Weiler T; Glass DN; Thompson SD; Thomson W; Wedderburn LR
    Pharmacogenet Genomics; 2010 Nov; 20(11):665-76. PubMed ID: 20827233
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Perceptions of Methotrexate Intolerance and Its Impact on Daily Life in School-Age Children with Juvenile Idiopathic Arthritis.
    Khan S; Mancini J; Hopper C; Rennick JE
    J Pediatr Nurs; 2019; 48():49-54. PubMed ID: 31254860
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 5-Aminoimidazole-4-carboxamide ribonucleotide-transformylase and inosine-triphosphate-pyrophosphatase genes variants predict remission rate during methotrexate therapy in patients with juvenile idiopathic arthritis.
    Pastore S; Stocco G; Moressa V; Zandonà L; Favretto D; Malusà N; Decorti G; Lepore L; Ventura A
    Rheumatol Int; 2015 Apr; 35(4):619-27. PubMed ID: 25240429
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adherence to low-dose methotrexate in children with juvenile idiopathic arthritis using a sensitive methotrexate assay.
    Möhlmann JE; de Roock S; Egas AC; Weijden ET; Doeleman MJH; Huitema ADR; van Luin M; Swart JF
    Pediatr Rheumatol Online J; 2024 May; 22(1):52. PubMed ID: 38715014
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Responses of patients with juvenile idiopathic arthritis to methotrexate: a genomic outlook.
    Selvestrel D; Lucafò M; Pugnetti L; Pagarin S; Moressa V; Pastore S; Taddio A; Stocco G; Decorti G
    Expert Rev Clin Immunol; 2021 Oct; 17(10):1131-1142. PubMed ID: 34392756
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The impact of single nucleotide polymorphisms in ADORA2A and ADORA3 genes on the early response to methotrexate and presence of therapy side effects in children with juvenile idiopathic arthritis: Results of a preliminary study.
    Roszkiewicz J; Michałek D; Ryk A; Swacha Z; Szmyd B; Smolewska E
    Int J Rheum Dis; 2020 Nov; 23(11):1505-1513. PubMed ID: 32969158
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Methotrexate in juvenile idiopathic arthritis: advice and recommendations from the MARAJIA expert consensus meeting.
    Ferrara G; Mastrangelo G; Barone P; La Torre F; Martino S; Pappagallo G; Ravelli A; Taddio A; Zulian F; Cimaz R;
    Pediatr Rheumatol Online J; 2018 Jul; 16(1):46. PubMed ID: 29996864
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Psychological side effects of MTX treatment in juvenile idiopathic arthritis: a pilot study.
    van der Meer A; Wulffraat NM; Prakken BJ; Gijsbers B; Rademaker CM; Sinnema G
    Clin Exp Rheumatol; 2007; 25(3):480-5. PubMed ID: 17631750
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A comparison of three treatment strategies in recent onset non-systemic Juvenile Idiopathic Arthritis: initial 3-months results of the BeSt for Kids-study.
    Hissink Muller PC; Brinkman DM; Schonenberg D; Koopman-Keemink Y; Brederije IC; Bekkering WP; Kuijpers TW; van Rossum MA; van Suijlekom-Smit LW; van den Berg JM; Allaart CF; Ten Cate R
    Pediatr Rheumatol Online J; 2017 Feb; 15(1):11. PubMed ID: 28166785
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacological conditioning for juvenile idiopathic arthritis: a potential solution to reduce methotrexate intolerance.
    Smits RM; Veldhuijzen DS; van Middendorp H; Hissink Muller PCE; Armbrust W; Legger E; Wulffraat NM; Evers AWM
    Pediatr Rheumatol Online J; 2020 Feb; 18(1):12. PubMed ID: 32033577
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA): a multicentre randomised open-label clinical trial.
    Tynjälä P; Vähäsalo P; Tarkiainen M; Kröger L; Aalto K; Malin M; Putto-Laurila A; Honkanen V; Lahdenne P
    Ann Rheum Dis; 2011 Sep; 70(9):1605-12. PubMed ID: 21623000
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Attitudes and Approaches for Withdrawing Drugs for Children with Clinically Inactive Nonsystemic JIA: A Survey of the Childhood Arthritis and Rheumatology Research Alliance.
    Horton DB; Onel KB; Beukelman T; Ringold S
    J Rheumatol; 2017 Mar; 44(3):352-360. PubMed ID: 28148696
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Successful treatment of methotrexate intolerance in juvenile idiopathic arthritis using eye movement desensitization and reprocessing - treatment protocol and preliminary results.
    Höfel L; Eppler B; Storf M; Schnöbel-Müller E; Haas JP; Hügle B
    Pediatr Rheumatol Online J; 2018 Feb; 16(1):11. PubMed ID: 29433504
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Methotrexate: new uses for an old drug.
    Hashkes PJ; Becker ML; Cabral DA; Laxer RM; Paller AS; Rabinovich CE; Turner D; Zulian F
    J Pediatr; 2014 Feb; 164(2):231-6. PubMed ID: 24286573
    [No Abstract]   [Full Text] [Related]  

  • 36. Methotrexate treatment may prevent uveitis onset in patients with juvenile idiopathic arthritis: experiences and subgroup analysis in a cohort with frequent methotrexate use.
    Kostik MM; Gaidar EV; Hynnes AY; Dubko MF; Masalova VV; Snegireva LS; Chikova IA; Isupova EA; Nikitina TN; Serogodskaya ED; Kalashnikova OV; Ravelli A; Chasnyk VG
    Clin Exp Rheumatol; 2016; 34(4):714-8. PubMed ID: 27385618
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination therapy with methotrexate and cyclosporine A in juvenile idiopathic arthritis.
    Ravelli A; Moretti C; Temporini F; Rossi F; Magni-Manzoni S; Pistorio A; Martini A
    Clin Exp Rheumatol; 2002; 20(4):569-72. PubMed ID: 12175118
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Transcriptional profiles of JIA patient blood with subsequent poor response to methotrexate.
    Moncrieffe H; Bennett MF; Tsoras M; Luyrink LK; Johnson AL; Xu H; Dare J; Becker ML; Prahalad S; Rosenkranz M; O'Neil KM; Nigrovic PA; Griffin TA; Lovell DJ; Grom AA; Medvedovic M; Thompson SD
    Rheumatology (Oxford); 2017 Sep; 56(9):1542-1551. PubMed ID: 28582527
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-adalimumab antibodies in juvenile idiopathic arthritis: frequent association with loss of response.
    Skrabl-Baumgartner A; Erwa W; Muntean W; Jahnel J
    Scand J Rheumatol; 2015; 44(5):359-62. PubMed ID: 25974288
    [TBL] [Abstract][Full Text] [Related]  

  • 40. British isles survey of methotrexate monitoring practice during treatment of juvenile idiopathic arthritis.
    Hawley DP; Camina N; Rangaraj S
    Semin Arthritis Rheum; 2011 Feb; 40(4):358-64.e1-2. PubMed ID: 20822799
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.